Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR/B7H3 CAR-T in Advanced Lung and Triple-negative Breast Cancer
NCT05341492Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- May 2022
- Primary completion
- May 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EGFR/B7-H3 CAR-T in lung cancer and triple-negative breast cancer (TNBC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Safety by Common Terminology Criteria for Adverse Events (CTCAE) V5.0 at 52 weeks. Started May 2022; status: recruiting.
02
Drugs
EGFR/B7-H3 CAR-T
03
Conditions
lung cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05341492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341492.